Compound ID	CDAMM02364
Common name	Ascorbigen
IUPAC name	3,6,6a-trihydroxy-6-(1H-indol-3-ylmethyl)-3,3a-dihydro-2H-furo[3,2-b]furan-5-one
Molecular formula	C₁₅H₁₅NO₆

Experimental data

Retention time	8.33
Adduct	[M+H]+
Actual mz	306.097
Theoretical mz	306.097
Error	0.25
Ionizaton mode	Positive
Instrument type	LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score	6.1709

Identifiers and class information

Inchi key	OMSJCIOTCFHSIT-UHFFFAOYNA-N
Smiles	O=C1OC2C(O)COC2(O)C1(O)CC3=CNC=4C=CC=CC43
Superclass	Organoheterocyclic compounds
Class	Furofurans

Plant source

Asparagus gonoclados Baker

Convolvulus prostratus Forssk.

External sources

HMDB ID	HMDB0029839
KNApSAcK ID
FooDB ID	FDB001054
DrugBank ID
ChEBI ID	CHEBI:64944
Pubchem Compound ID	358022
PlantCyc ID	CPDQT-426
UNPD ID	UNPD159999
Coconut ID	CNP0290671
LipidMAPS ID
NANPDB ID

Pharmacokinetic properties

Number of descriptor values(#stars)	0
Number of non-conjugated amine groups (#amine)	0
Number of amidine and guanidine groups (#amidine)	0
Number of carboxylic acid groups (#acid)	0
Number of non-conjugated amide groups (#amide)	0
Number of rotatable bonds (#rotor)	5
Number of reactive functional groups (#rtvFG)	1
Predicted central nervous system activity (CNS)	-2
Molecular weight (mol_MW)	305.287
Computed dipole moment(dipole)	6.873
Total solvent accessible surface area (SASA)	483.115
Hydrophobic component of SASA (FOSA)	120.425
Hydrophilic component of SASA (FISA)	178.801
Pie component of the SASA (PISA)	183.889
Weakly polar component of the SASA (WPSA)	0
Total solvent accesible volume (volume)	866.323
Number of hydrogen bond donors (donorHB)	4
Number of hydrogen bond acceptors (accptHB)	6.95
Free energy of solvation of dipole (dip^2/V)	0.0545301
Index of cohesive interaction in solids (ACxDN^.5/SA)	0.0287716
Globularity descriptor (glob)	0.909706
Predicted polarizability in cubic angstroms (QPpolrz)	27.062
Predicted hexadecane/gas partition coefficient (QPlogPC16)	9.988
Predicted octanol/gas partition coefficient (QPlogPoct)	19.267
Predicted water/gas partition coefficient (QPlogPw)	14.95
Predicted octanol/water partition coefficient (QPlogPo/w)	0.617
Predicted aqueous solubility (QPlogS)	-2.189
Conformation-independent predicted aqueous solubility (CIQPlogS)	-3.321
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)	-3.87
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)	199.677
Predicted brain/blood partition coefficient (QPlogBB)	-1.178
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)	86.714
Predicted skin permeability, log Kp (QPlogKp)	-3.687
PM3 calculated ionization potential (IP(ev))	8.27
PM3 calculated electron affinity (EA(eV))	-0.039
Number of likely metabolic reactions (#metab)	3
Prediction of binding to human serum albumin (QPlogKhsa)	-0.43
Predicted qualitative human oral absorption (HumanOralAbsorption)	3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)	71.729
Solvent-accessible surface area of fluorine atoms (SAFluorine)	0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)	0
Van der Waals surface area (PSA)	119.581
Number of nitrogen and oxygen atoms (#NandO)	7
Number of violations of Lipinski’s rule of five (RuleOfFive)	0
Number of violations of Jorgensen’s rule of three (RuleOfThree)	0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID	Gene name	Target name	TTD_ID	Prediction source
P21917	DRD4	Dopamine D4 receptor	T24983	SEA
P14416	DRD2	Dopamine D2 receptor	T67162	SEA
P28566	HTR1E	Serotonin 1e (5-HT1e) receptor	T84117	SEA
P35462	DRD3	Dopamine D3 receptor	T02551	SEA
P35270	SPR	Substance-P receptor	T47094	SEA
P32245	MC4R	Melanocortin receptor 4	T72458	SEA
P42892	ECE1	Endothelin-converting enzyme 1	T50970	SEA
P31391	SSTR4	Somatostatin receptor 4	T62974	SEA
P30872	SSTR1	Somatostatin receptor 1	T16633	SEA
P32745	SSTR3	Somatostatin receptor 3	T13644	SEA
P21452	TACR2	Neurokinin 2 receptor	T52790	SEA
P33032	MC5R	Melanocortin receptor 5	T95302	SEA
P28336	NMBR	Neuromedin B receptor	T68887	SEA
Q06609	RAD51	DNA repair protein RAD51 homolog 1	T63083	SEA

Target associated diseases

TTD_ID	Disease_ID	Disease name	ICD_11	Uniprot ID	Gene names
T24983	DI0022	Allergic/hypersensitivity disorder	[ICD-11: 4A80-4A8Z]	P21917	DRD4
T24983	DI0370	Schizophrenia	[ICD-11: 6A20]	P21917	DRD4
T67162	DI0022	Allergic/hypersensitivity disorder	[ICD-11: 4A80-4A8Z]	P14416	DRD2
T67162	DI0025	Alzheimer disease	[ICD-11: 8A20]	P14416	DRD2
T67162	DI0037	Asthma	[ICD-11: CA23]	P14416	DRD2
T67162	DI0040	Attention deficit hyperactivity disorder	[ICD-11: 6A05]	P14416	DRD2
T67162	DI0051	Bipolar disorder	[ICD-11: 6A60]	P14416	DRD2
T67162	DI0063	Breathing abnormality	[ICD-11: MD11]	P14416	DRD2
T67162	DI0070	Cardiovascular disease	[ICD-11: BA00-BE2Z]	P14416	DRD2
T67162	DI0073	Cerebral ischaemia	[ICD-11: 8B1Z]	P14416	DRD2
T67162	DI0117	Depression	[ICD-11: 6A70-6A7Z]	P14416	DRD2
T67162	DI0124	Digestive system disease	[ICD-11: DE2Z]	P14416	DRD2
T67162	DI0137	Essential hypertension	[ICD-11: BA00]	P14416	DRD2
T67162	DI0142	Faecal incontinence	[ICD-11: ME07]	P14416	DRD2
T67162	DI0156	Gangrene	[ICD-11: MC85]	P14416	DRD2
T67162	DI0166	Glaucoma	[ICD-11: 9C61]	P14416	DRD2
T67162	DI0175	Heart failure	[ICD-11: BD10-BD1Z]	P14416	DRD2
T67162	DI0185	Hyperaemia	[ICD-11: 9A61-9B7Y]	P14416	DRD2
T67162	DI0190	Hypertension	[ICD-11: BA00-BA04]	P14416	DRD2
T67162	DI0196	Hypotension	[ICD-11: BA20-BA21]	P14416	DRD2
T67162	DI0205	Inborn porphyrin/heme metabolism error	[ICD-11: 5C58]	P14416	DRD2
T67162	DI0214	Insomnia	[ICD-11: 7A00-7A0Z]	P14416	DRD2
T67162	DI0222	Itching	[ICD-11: 1F28-1G07]	P14416	DRD2
T67162	DI0264	Migraine	[ICD-11: 8A80]	P14416	DRD2
T67162	DI0293	Nausea/vomiting	[ICD-11: MD90]	P14416	DRD2
T67162	DI0324	Pain	[ICD-11: MG30-MG3Z]	P14416	DRD2
T67162	DI0331	Parkinsonism	[ICD-11: 8A00]	P14416	DRD2
T67162	DI0337	Pituitary gland disorder	[ICD-11: 5A60-5A61]	P14416	DRD2
T67162	DI0340	Postpartum haemorrhage	[ICD-11: JA43]	P14416	DRD2
T67162	DI0354	Psychotic disorder	[ICD-11: 6A20-6A25]	P14416	DRD2
T67162	DI0356	Pulmonary hypertension	[ICD-11: BB01]	P14416	DRD2
T67162	DI0370	Schizophrenia	[ICD-11: 6A20]	P14416	DRD2
T67162	DI0396	Substance abuse	[ICD-11: 6C40]	P14416	DRD2
T67162	DI0408	Thyrotoxicosis	[ICD-11: 5A02]	P14416	DRD2
T67162	DI0417	Type 2 diabetes mellitus	[ICD-11: 5A11]	P14416	DRD2
T84117	DI0337	Pituitary gland disorder	[ICD-11: 5A60-5A61]	P28566	HTR1E
T02551	DI0051	Bipolar disorder	[ICD-11: 6A60]	P35462	DRD3
T02551	DI0331	Parkinsonism	[ICD-11: 8A00]	P35462	DRD3
T47094	DI0117	Depression	[ICD-11: 6A70-6A7Z]	P35270	SPR
T47094	DI0293	Nausea/vomiting	[ICD-11: MD90]	P35270	SPR
T72458	DI0192	Hypoactive sexual desire dysfunction	[ICD-11: HA00]	P32245	MC4R
T72458	DI0228	Large intestine motility disorder	[ICD-11: DB32]	P32245	MC4R
T72458	DI0308	Obesity	[ICD-11: 5B80-5B81]	P32245	MC4R
T62974	DI0087	Chronic pain	[ICD-11: MG30]	P31391	SSTR4
T62974	DI0179	Hepatitis virus infection	[ICD-11: 1E50-1E51]	P31391	SSTR4
T16633	DI0108	Cushing syndrome	[ICD-11: 5A70]	P30872	SSTR1
T16633	DI0395	Stomach cancer	[ICD-11: 2B72]	P30872	SSTR1
T13644	DI0108	Cushing syndrome	[ICD-11: 5A70]	P32745	SSTR3
T52790	DI0218	Irritable bowel syndrome	[ICD-11: DD91]	P21452	TACR2
T95302	DI0005	Acne vulgaris	[ICD-11: ED80]	P33032	MC5R
T95302	DI0371	Sebaceous gland disorder	[ICD-11: ED91]	P33032	MC5R
T68887	DI0062	Breast cancer	[ICD-11: 2C60-2C6Y]	P28336	NMBR
T68887	DI0391	Solid tumour/cancer	[ICD-11: 2A00-2F9Z]	P28336	NMBR
T63083	DI0048	B-cell lymphoma	[ICD-11: 2A86]	Q06609	RAD51
T63083	DI0391	Solid tumour/cancer	[ICD-11: 2A00-2F9Z]	Q06609	RAD51